Trial
NCT03107780
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Glioblastoma
Intervention
Biospecimen Collection
Why stopped
Drug supply issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-13